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ABSTRACT
MODELING ANTIBIOTIC RESISTANCE WHEN ADDING A NEW
ANTIBIOTIC TO A HOSPITAL SETTING
by Brandi N. Canter
As of now, not many pharmaceutical companies are producing new categories
of antibiotics to fight bacterial infections [10]. Therefore, bacteria are building up a
resistance to the medications commonly used. Often, antibiotic resistance begins
within a hospital. To combat resistance, researchers completed several studies using
cycling of the medications that are already in place, but they found either no
improvement or the resistance increased with this type of setting
[3, 8, 16, 12, 21, 22]. In addition, although preventative infection control measures
have been shown to decrease antibiotic resistance for some antibiotics, the level of
antibiotic resistance found in hospitals is still extremely high [9, 14]. This motivates
the main goal of this thesis: to quantify how much the overall resistance can be
lowered by simply adding one new drug to the regimen.
The process of adding a new antibiotic can be quantified using mathematical
models that show the flow of patients colonized with various types of bacteria into,
out of, and within the hospital. Deterministic models can be used to model the
spread of resistant bacteria in hospitals with a relatively large number of beds.
However, not all hospitals are large enough to accurately determine the effects using
a deterministic model; thus, we must use stochastic models, where mathematical
formulations include probability in ways that describe intrinsic random fluctuations,
typical of infection processes at smaller scales [2, 20].
In examining the addition of a new antibiotic within a hospital, we consider
different administration protocols, either assuming that physicians are equally likely
to prescribe the new antibiotic as they are to prescribe existing antibiotics or that
physicians prescribe the new antibiotic to only a targeted population of patients.
We will examine the variation in the expected level of overall resistance in a hospital
depending on the administration procedure as well as the whether the hospital is
large (deterministic model) or small (stochastic model). We will conclude with
initial results for fitting these models to simulated data using common inverse
problem methodology.
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CHAPTER 1
INTRODUCTION
Public health is a major concern to all and when something as serious as
antibiotic resistance threatens the traditional way of medicine, we need to be
concerned. We need to pay close attention to antibiotic resistance; the goal should
be to effectively treat patients by using current antibiotics wisely and focus on the
manufacture of new antibiotics. As of now, “...[it] is estimated that each year,
antibiotic resistance in the United States alone results in $20 billion of excess health
care costs. . . . Furthermore, the CDC estimates that resistant infections result in a
total of 8 million additional days that people spend in the hospital each year” [12].
Joyner [12] states that “[today], we attribute longer survival of severely ill patients
and longer life expectancy in the elderly to increase use of antibiotics”. Some
scientists have found the following practices are . . .
risk factors for the development of antibiotic resistance:
excessive and irrational over-utilization of antibiotics in outpatient
practice and in hospitalized patients, either therapeutically or
prophylactically, use of antibiotics in agricultural industry,
particularly in the production of food, longer survival of severely ill
patients, longer life expectancy with increased use of antibiotics in
the elderly, advances in medical science have resulted in the survival
of many patients with severe illness and at risk for infections:
Critically ill patients, Immunosuppression, Congenital diseases (i.e.
cystic fibrosis), lack of use of proven and effective preventive
infection control measure such as hand washing, antibiotic usage
restrictions and proper isolation of patients with resistant infections,
increased use of invasive procedures, and increased use of prosthetic
devices and foreign bodies amenable to super infection with
resistant bacteria [1].
Although antibiotics have cured many life threatening diseases, the increased
use of antibiotics comes with side effects. It has been shown by the World Heath
2Organization [18] that increased use of antibiotics can lead bacteria to form defenses
and become resistant to the prescription drugs which is called antibiotic resistance.
These resistant bacteria can become a catastrophic problem causing normal
infections to become harder and sometimes impossible to treat. Once an individual
is colonized with bacteria resistant to a particular antibiotic, that individual can
spread the resistant bacteria either by direct contact or indirect contact through a
secondary source such as a healthcare worker in a hospital. Hospital stays could
become a problem for both the patient and the healthcare provider resulting in
costlier stays [17]. This situation can be improved if we can determine how the
resistant strains spread and then how to limit this spread. Mathematical models can
aid in describing the spread of resistant bacteria.
Once a mathematical model is developed with an accurate description of the
process involved in the transfer of resistant bacteria within an environment, it can
be used as a tool to measure the quantitative effects of various protocols on the
reduction of the prevalence of resistant bacteria. Lipsitch and Samore [15] state,
“. . . [mathematical models] can be particularly valuable in at least four ways: 1)
generating hypotheses about the relationship between antibiotic use and resistance
that can be used in designing and prioritizing empirical studies; 2) defining the
conditions under which a particular intervention is likely to work, thereby
suggesting how empirical results can (and cannot) be extrapolated to other settings;
3) providing explanations for phenomena that have been observed but whose causes
were uncertain; and 4) identifying biological mechanisms that, while important,
remain poorly understood”.
Many mathematical models can be found in literature describing various
aspects of antibiotic resistance. A few of the models have tested protocols involving
current antibiotics such as mixing versus cycling, a process which takes a limited
3number of antibiotics, normally two, and uses one for a specific amount of time and
then switches to the other medication [14, 15]. Another protocol is isolation where
patients isolated from the general population, such as to another wing of the
hospital [6, 9]. Bergstrom et. al. [6] consider a scenario in which two antibiotics
were used in a cycling protocol, considering only the presence of resistance to only a
single antibiotic. Dual resistance, i.e. resistance to two antibiotics, was assumed to
be negligible. In this scenario, mixing (using two antibiotics in a random manner)
appeared to be a better administration protocol than cycling the antibiotics. Chow
et. al. [9] include the effects of the dual resistance and the competition between the
spread of bacteria resistant to a singular antibiotic versus resistance to two
antibiotics. In this scenario, simulations indicated cycling reduced the spread of
dual resistant bacteria while increasing the spread of single resistant bacteria.
Therefore, they concluded that neither cycling nor mixing caused much impact on
the overall proportion of the hospital colonized with a resistant strain of bacteria.
Although isolation reduced the spread of resistant bacteria slightly, simulations
suggest there would still be a significant proportion of the patients colonized with
resistant bacteria even when isolation practices are implemented.
Therefore, the goal of this thesis is to determine the effect of the introduction
of a new antibiotic on the proportion of patients colonized with resistant bacteria
and how to effectively introduce these new drugs when they are produced. If one
can determine how to utilize the new drugs most effectively then it might be
possible to reduce the widespread incidence of resistance.
In Chapter 2, we will develop deterministic models which depict the
introduction of a new antibiotic under various administration procedures within a
hospital setting. Although deterministic models can be accurately used to describe
the spread of antibiotic resistance when there is a large number of patients in a
4hospital, we must use stochastic models for small hospitals or single units of a large
hospital such as an intensive care unit. Therefore, Chapter 3 will focus on the
corresponding stochastic models. In Chapter 4, we will examine the inverse problem
which can be used to determine a subset of parameters found in the models
developed in Chapters 2 and 3. Finally, in Chapter 5 we conclude with some closing
remarks and directions for future work.
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DETERMINISTIC MODELING OF ANTIBIOTIC RESISTANCE
In this chapter we will develop three deterministic models which describe the
spread of resistant bacteria in a hospital and quantify the effects of introducing a
new drug on this spread. Since the goal of this thesis is to determine how
introducing a new antibiotic in the hospital effects the overall level of patients
colonized with resistant bacteria, a base model is used as a comparison which is
established based on the model developed by Chow et. al. [9]. The Base Model
illustrates the spread of the resistant bacteria with no prevention protocols. Two
additional models are developed, the Random Drug Model and the Targeted Drug
Model which both illustrate adding a new drug under different administration
protocols; all the patients are equally likely to receive the antibiotic (Random Drug
Model) or a targeted population only receives the new antibiotic (Targeted Drug
Model).
We are focusing “. . . on the introduction of an entirely new antibiotic as
opposed to simply an upgrade of an antibiotic within the same class as the drugs
already employed in the hospital. Due to chromosomal mutations or acquisition of
new genetic material leading to the development of resistant bacteria, if a new
antibiotic is introduced which is an upgrade of a current antibiotic, the use of the
new antibiotic on patients already colonized with bacteria resistant to the older
antibiotic could lead to a new high-level resistant strain” [13]. A comparison
between a next-generation antibiotic and a new class of antibiotic can be found in
[12]. In addition, since we are considering an entirely new class of antibiotics,
resistance to the new antibiotic is neglected since the initial mutation rate is
6presumed to be on the order of 10−6 [7, 16, 19]. Given this rate and the fact that
resistance to the new antibiotic could be treated with either of the two existing
antibiotics, we assume resistance to the new antibiotic would be minimal compared
to other resistant populations within the system.
2.1 The Base Model
First, we examine in detail the Base Model from which both the Random
Drug Model and Targeted Drug Models are derived. This model incorporates
patients who are colonized with bacteria resistant to both one and two drugs,
denoted “single” or “dual” resistant, respectively. We are assuming here that there
are only two antibiotics in the model and that some of the patients may be
colonized with bacteria resistant to either one drug or both drugs or neither. It is
assumed there is no antibiotic present to treat the patients resistant to both drugs,
other than their own body’s ability to fight off the infection, a process known as
“spontaneous clearance”. Figure 2.1 gives a schematic for the Base Model.
Figure 2.1: Schematic of the Base Model
7The overall model, the grey box in Figure 2.1, represents a hospital with a fixed
population size N , where N represents 100% of the total hospital population.
Proportions of patients can be categorized in one of five possible compartments, S,
R1, R2, R12, and X. The state variable S represents the proportion of patients in
the hospital who are colonized with bacteria sensitive to both drugs in the model.
Therefore, S is the number of patients colonized with sensitive bacteria divided by
the total population. Sensitive patients can be effectively treated and cleared with
either drug 1 or drug 2. The uncolonized group, X, represents the proportion of
patients in the hospital who are not colonized with bacteria (other than natural
bacteria). The compartments R1 and R2 represent the proportion of patients
colonized with single resistant bacteria, either bacteria resistant to drug 1, R1, or
resistant to drug 2, R2. The main difference between these groups is the type of
drug which will effectively treat the patients. Patients in compartment R1 can only
be effectively treated with drug 2, and patients in R2 can only be effectively treated
with drug 1. the compartment R12 is the proportion of “dual resistant” patients in
the hospital, because they cannot be effectively treated with either drug 1 or drug 2.
In other words, they are colonized with bacteria resistant to both drugs. A
summary of the state variables can be found in Table 2.1. As all the state variables
are considered as proportions of patients within the hospital, we have conservation
of mass
1 = S +X +R1 +R2 +R12. (2.1)
Only a fixed proportion of the total population is assumed to be treated with
antibiotics which is consistent with data found in literature [13]. Physicians
prescribe either drug 1 or drug 2. The rate at which the doctors prescribe drug 1 is
denoted by τ1 and, similarly, τ2 is the rate at which doctors prescribe drug 2.
8Although doctors freely prescribe either of the drugs; patients colonized with
bacteria resistant to a single antibiotic, R1 or R2, will only be effectively treated
with one of the two antibiotics. Patients colonized with bacteria resistant to both
drugs, R12, will be unaffected by the prescription of either antibiotic; whereas,
patients colonized with bacteria sensitive to either drug will be effectively treated by
both.
Table 2.1: The Definition of Model Variables
Variables Description
S Proportion of patients colonized
with bacteria sensitive to both drugs
Ri Proportion of patients colonized
with bacteria resistant to drug i, i = 1, 2
R12 Proportion of patients colonized
with bacteria resistant to both drugs
X Proportion of patients uncolonized
As mentioned previously, it is assumed the total number of patients within the
hospital remain fixed 2.1. Therefore, for every one person entering the hospital,
there must be exactly one person who is discharged. We assume patients enter and
leave the hospital at a constant rate, µ, which is given by the reciprocal of the
average number of days of stay in the hospital. Furthermore, it is assumed patients
can enter the hospital in any of the given compartments. The proportion of patients
entering the hospital with bacteria susceptible to both drugs is given by mS. The
proportion of patients entering colonized with a single resistant bacteria is given by
m1 and m2 for single resistance to drug 1 and single resistance to drug 2,
respectively. The proportion of patients entering the hospital colonized with dual
resistant bacteria is given by m12. Therefore, the proportion of patients admitted to
the hospital uncolonized, mX , can be given by mX = 1− (ms +m1 +m2 +m12).
9The total admission rate is then given by
µmS + µm1 + µm2 + µ12 + µmX .
Substituting for mX , we get the total admission rate
µmS + µm1 + µm2 + µ12 + µ[1− (ms +m1 +m2 +m12)] = µ.
Similarly, it is assumed patients can be discharged from any compartment where the
proportion of patients discharged per day from a particular compartment is µ times
the total proportion in that compartment at time t. For example, µS is the
proportion of patients colonized with susceptible bacteria discharged per day. The
proportion discharged in each compartment is computed in a similar manner.
Therefore, µX is the proportion of uncolonized patients discharged per day. µR1
and µR2 represent the proportion of single resistant patients discharged per day and
lastly, µR12 is the proportion of the dual resistant patients discharged from the
hospital per day. So, the total discharge rate from the hospital is given by
µS + µX + µR1 + µR2 + µR12 = µ(S +R1 +R2 +R12 +X) = µ(1) = µ.
As stated the admission and discharge rates are both given by µ.
We assume that interactions between the different groups, S, X, R1, R2, and
R12, can take place either directly or indirectly through healthcare workers. For
example, suppose a nurse checks on a patient colonized with bacteria resistant to
drug 1 and does not strictly follow the hand-hygiene rules. Then that nurse may act
as an indirect vector in the colonization of patients when checking on other patients.
It is assumed that an average patient in the hospital makes βN effective contacts
with other patients per unit time through either direct contact or similar indirect
contact. This assumption of a rate of contact per infective proportional to the
10
population size N is called the mass action incidence [11]. The probability that a
random contact is made by a patient colonized with sensitive bacteria with an
uncolonized patient is given by the number of uncolonized patients divided by the
total population. Therefore, the proportion of the patients in the hospital gained by
new colonizations in a unit time by contact is βX. Thus, the rate of transfer from
compartment X to compartment S is given by βXS. In a similar manner,
uncolonized patients, X, may become colonized with bacteria resistant to drug 1,
drug 2, or both and hence move from X to either R1, R2, or R12, respectively. The
terms representing these movements are similar to the movement from X to S
except the probability of becoming colonized with resistant bacteria is offset by the
fitness cost of the resistant bacteria represented by the parameters c1, c2, and c12.
The fitness cost of bacteria resistant to drug 1 is c1, c2 is the fitness cost of bacteria
resistant to drug 2, and, likewise, c12 is the fitness cost of the dual resistant bacteria.
Fitness cost is a parameter which describes the rate at which
resistant bacteria revert back to being susceptible in the absence of
antibiotic treatment. Resistant bacteria thrive in the presence of
antibiotics; however, in an antibiotic-free environment, the resistant
bacteria are at a disadvantage and less able to reproduce, thus
providing an advantage to the susceptible bacteria. When the
fitness cost is high, the ability to reproduce is much lower and thus
more difficult to spread. On the other hand, the lower the fitness
cost of the resistant bacteria, the easier it is for the bacteria to
spread. ...we assume ... that the dual resistant strain is harder to
spread and, therefore, has a higher fitness cost than the single
resistant bacteria [13].
In other words, if c1 is reduced then the term (1− c1) is increased taking into
account that bacteria spreads at a faster rate. The same is true for c2 and c12.
Patients may also move from S to X by being effectively treated with either
drug 1 or drug 2, or through the process of spontaneous clearance, represented by
the terms τ1S, τ2S, and γS respectively. Combining these together, we obtain the
11
rate at which patients colonized with sensitive bacteria move from S to X,
(τ1 + τ2 + γ)S.
Similarly patients may transfer from either R1, R2, or R12 to X. However, in
each of these instances either only one antibiotic will work (R1, R2) or none (R12).
We are again assuming that physicians are unaware of the type of bacteria present.
Hence, if patients are colonized with bacteria resistant to drug 1, they will not be
cleared until treated with drug 2, represented by the term τ2R1, or by spontaneous
clearance, γR1. Terms for R2 and R12 can be found in the schematic in Figure 2.1.
It is assumed that patients cannot be colonized with more than one strain of
bacteria at a given time. Furthermore, the bacteria with the lowest fitness, thus the
quickest rate of reproduction will “win” out over any competing bacteria. It is
assumed that bacteria resistant to multiple antibiotics has a more difficult time
reproducing [9], thus the dual resistant bacteria will never “out-compete” the single
resistant bacteria nor the susceptible bacteria. Therefore, we assume patients
colonized with dual resistant bacteria may move from R12 to either R1, R2, or S;
however, patients in R1, R2, or S are never assumed to move to R12 simply through
interactions. (We are neglecting the possibility of conjugation in this paper.) If the
fitness cost of drug 1 (c1) is larger than the fitness cost of drug 2 (c2), bacteria
resistant to drug 2 out-competes bacteria resistant to drug 1. This process of one
type of bacteria out-competing another type is considered secondary colonization
and is represented by the term σ. Combining all these terms, we have a system of
nonlinear ordinary differential equations describing the Base Model as follows where
the definitions for the parameters are given in Table 2.2.
12
dS
dt
= (mS − S)µ− (τ1 + τ2 + γ)S + βXS + βσ(c1R1 + c2R2 + c12R12)S
dR1
dt
= (m1 −R1)µ− (τ2 + γ)R1 + β(1− c1)XR1
+σβ[(c12 − c1)R12 + (c2 − c1)R2 − c1S]R1
dR2
dt
= (m2 −R2)µ− (τ1 + γ)R2 + β(1− c2)XR2
+σβ[(c12 − c2)R12 + (c1 − c2)R1 − c2S]R2
dR12
dt
= (m12 −R12)µ− γR12 + β(1− c12)XR12
−σβ[c12S + (c12 − c1)R1 + (c12 − c2)R2]R12
dX
dt
= (mX −X)µ+ (τ1 + τ2 + γ)S + (τ2 + γ)R1 + (τ1 + γ)R2 + γR12
−βX(S + (1− c1)R1 + (1− c2)R2 + (1− c12)R12).
(2.2)
Table 2.2: The Definition of Parameters
Parameters Description Units
β Per capita primary transmission rate 1/day
(colonization rate)
σ Relative rate of secondary colonization Dimensionless
to that of primary colonization
ci Fitness cost of bacteria resistant to drug i, i = 1, 2 Dimensionless
c12 Fitness cost of bacteria resistant to both drugs Dimensionless
τi Per capita treatment rate of drug i, i = 1, 2 1/day
γ Per capita clearance rate of bacteria 1/day
due to immune response
µ Per capita patient turnover rate in hospital 1/day
mS Proportion of admitted patients Dimensionless
colonized with sensitive bacteria
mi Proportion of admitted patients Dimensionless
colonized with bacteria resistant to drug i, i = 1, 2
m12 Proportion of admitted patients Dimensionless
colonized with bacteria resistant to both drugs
2.2 The Random Drug Model
The objective of this thesis is to determine what happens to the total level of
patients colonized with resistant bacteria within the hospital when a completely new
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drug is added to the prescription regimen. In both the Random Drug and Targeted
Drug Models, we are adding a new antibiotic, referred to as drug 3, to the regimen
to see if the overall total proportion of patients colonized with resistant bacteria is
lowered. The difference between these models is in the population that receives the
new medication. In the Random Drug Model, we are assuming that the doctors can
give any of the three drugs to all patients. In other words, we are assuming there is
an equal likelihood the doctors will choose drug 1, drug 2, or drug 3. The per capita
treatment rates of drugs 1, 2, and 3 are given by τ1, τ2, and τ3, respectively, where it
is assumed τ1 = τ2 = τ3.
Although a new antibiotic is added to the regimen, we assume that the total
population being treated per day, T , remains the same as the Base Model. Thus,
T = τ1 + τ2 + τ3 where τi =
T
3
for i = 1, 2, 3. This inherently means that when we
add the third drug, we are lowering the per capita treatment rates of drug 1 and 2.
Although we still assume physicians do not know what type of bacteria each patient
has contracted, two drugs are now effective for patients colonized with single
resistant bacteria. Furthermore, patients colonized with dual resistant bacteria now
have a mechanism for clearance other than their own immune system. As with the
Base Model, there is a possibility that patients will initially be given a medication
that does not work. For example, if a patient is in the R1 compartment and given
drug 1, the patient will not be cleared. However, if they are given drug 2 or drug 3
in the Random Drug Model, they will become uncolonized. Figure 2.2 shows a
schematic fro the Random Drug Model.
14
Figure 2.2: Schematic of the Random Drug Model
The set of differential equations representing the model are as follows:
dS
dt
= (mS − S)µ− (τ1 + τ2 + τ3 + γ)S + βXS
+βσ(c1R1 + c2R2 + c12R12)S
dR1
dt
= (m1 −R1)µ− (τ2 + τ3 + γ)R1 + β(1− c1)XR1
+σβ[(c12 − c1)R12 + (c2 − c1)R2 − c1S]R1
dR2
dt
= (m2 −R2)µ− (τ1 + τ3 + γ)R2 + β(1− c2)XR2
+σβ[(c12 − c2)R12 + (c1 − c2)R1 − c2S]R2
dR12
dt
= (m12 −R12)µ− (τ3 + γ)R12 + β(1− c12)XR12
−σβ[c12S + (c12 − c1)R1 + (c12 − c2)R2]R12
dX
dt
= (mX −X)µ+ (τ1 + τ2 + τ3 + γ)S
+(τ2 + τ3 + γ)R1 + (τ1 + τ3 + γ)R2 + (τ3 + γ)R12
−βX[S + (1− c1)R1 + (1− c2)R2 + (1− c12)R12].
(2.3)
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2.3 The Targeted Drug Model
In the previous model, the Random Drug Model, we assumed that everyone
within the hospital could receive the third drug, because it was readily available to
physicians for prescription. The Targeted Drug Model assumes the new drug is only
used to target one group of patients, namely patients colonized with bacteria
resistant to both drugs 1 and 2. As with both of the previous models, the Targeted
Drug Model keeps the total proportion of patients being treated, T , fixed with
T = τ1 + τ2 + τ3; however, within the Targeted Drug Model, we are not making the
assumption that the three drugs are given at the same rate. In this model, we are
assuming that τ1 = τ2, therefore, drug 1 and drug 2 are given at the same rate per
day. However, the rate at which drug 3 is given, τ3, depends on the proportion, p,
we assume can be identified, by either testing or through treatment failure of drugs
1 and 2, as carrying the dual resistant strain. All those identified can then be
treated with the new antibiotic. Thus, τ3 = pR12 is a function of time, because R12
changes across time. It is intuitive that if the proportion of patients we can identify
increases, the treatment rate of drug 3 will also increase. Figure 2.3 depicts the
schematic for the Targeted Drug Model “. . . where the parameter δ = 1/day is
introduced only to help distinguish between the proportion of patients colonized
with dual resistance who are identified and treated, RT = pR12 (dimensionless
quantity), and the actual treatment rate with drug 3, τ3 = δpR12 (units 1/day)” [13].
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Figure 2.3: Schematic of the Targeted Drug Model
The system of differential equations describing the Targeted Drug Model are as
follows:
dS
dt = (mS − S)µ− (τ1 + τ2 + γ)S + βXS + βσ(c1R1 + c2R2 + c12R12)S
dR1
dt = (m1 −R1)µ− (τ2 + γ)R1 + β(1− c1)XR1 + σβ[(c12 − c1)R12 + (c2 − c1)R2 − c1S]R1
dR2
dt = (m2 −R2)µ− (τ1 + γ)R2 + β(1− c2)XR2 + σβ[(c12 − c2)R12 + (c1 − c2)R1 − c2S]R2
dR12
dt = (m12 −R12)µ− (δp+ γ)R12 + β(1− c12)XR12
−σβ[c12S + (c12 − c1)R1 + (c12 − c2)R2]R12
dX
dt = (mX −X)µ+ (τ1 + τ2 + γ)S + (τ2 + γ)R1 + (τ1 + γ)R2 + (δp+ γ)R12
−βX[S + (1− c1)R1 + (1− c2)R2 + (1− c12)R12].
(2.4)
2.4 Numerical Simulation Results
Results of numerical simulations are given in Figure 2.4 for each of the three
the models given parameter values in Table 2.3. Figure 2.4 also shows simulated
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results for a model not explained in this paper, namely the Isolation Model. This
model is shown for comparison purposes and was first introduced by Chow et. al.,
[9] and then further discussed by the author in [12]. In this model, patients
colonized with the dual resistant bacteria are isolated from the other patients at a
rate η. The theory is that patients will be less likely to spread the dual resistant
strain when isolated.
The simulations indicate that if there are no protocols for treatment of the
patients colonized with dual resistance, i.e. the Base Model, then on average across
100 days approximately 70% of the hospital population will become colonized with a
resistant strain. This proportion is only slightly reduced when isolation is practiced.
On the other hand, for the Random Drug Model, i.e., when a new antibiotic is used
at the same rate as the existing antibiotics and each patient is equally as likely to
receive drug 3 as drugs 1 or 2, the total proportion of the hospital colonized with a
resistant strain drops to 35%. This is a significant reduction from the 70% level for
the Base Model. The last plot in Figure 2.4 shows the state variables for the
Targeted Drug Model, using a value of p = .30. Recall, the value p is the percentage
we assume are able to be identified as being colonized with bacteria resistant to
drugs 1 and 2. Therefore, if one were able to identify and treat 30% of those
patients in the hospital who are colonized with bacteria resistant to both drugs, we
could lower the total proportion of patients colonized with any type of resistant
bacteria by an additional 3% over the Random Drug Model.
Figure 2.5 shows a comparison of the total resistance for each model while
varying p in the Targeted Drug Model. Since the Targeted Drug Model depends on
the proportion of patients carrying the dual resistant strain who can be identified, it
is necessary to analyze how varying the parameter p effects the total proportion of
patients colonized with a resistant strain in the hospital. If we cannot identify any
18
Table 2.3: Values of Model Parameters for the Deterministic Models [13]
Parameters Base Model Random Drug Targeted Drug
β 1/day 1/day 1/day
σ 0.25 0.25 0.25
γ 0.03/day 0.03/day 0.03/day
µ 0.10/day 0.10/day 0.10/day
mS 0.70 0.70 0.70
m1 0.05 0.05 0.05
m2 0.05 0.05 0.05
m12 0.04 0.04 0.04
mX 0.16 0.16 0.16
c1 0.05 0.05 0.05
c2 0.05 0.05 0.05
c12 0.15 0.15 0.15
τ1 0.39/day 0.26/day
1
2
(T − τ3)/day
τ2 0.39/day 0.26/day
1
2
(T − τ3)/day
τ3 - 0.26/day pR12/day
T - - 0.78/day
Figure 2.4: Comparison of All of the State Variables for Each Model
of the patients colonized with resistant bacteria (p = 0), the model is equivalent to
the Base Model. On the other hand, if p = 1, we assume we are able to identify and
treat all of the patients colonized with dual resistance. This scenario is unrealistic
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since hospitals do not test for resistance upon admittance. However, if we can
identify and treat approximately 25% or more of the patients colonized with the
dual resistant bacteria, the Targeted Drug Model is the best way to administer the
new drug. This method of administration could result in a reduction of total
resistance by approximately 40% over the Base Model!
Figure 2.5: Comparison of the Total Resistance for Each Model
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CHAPTER 3
STOCHASTIC MODELING OF ANTIBIOTIC RESISTANCE
In the previous chapter, we focused on deterministic models for the spread of
resistant bacteria within a hospital. In general, “deterministic models predict an
outcome with absolute certainty, whereas stochastic models provide only the
probability of an outcome” [2]. Stochastic models incorporate randomness into the
model. Each time a solution for a stochastic model is simulated, called a realization,
it is slightly different than another realization. However, as the population size of
our system becomes large, the mean of all the realizations of the stochastic model
approach the solution of the deterministic model. There are a variety of methods
and techniques used to formulate stochastic models based on the specific
application. In this paper, we will develop stochastic models which are based on
stochastic processes continuous in time with discrete state space in Z5. These are
called continuous-time Markov chain (CTMC) models [2]. Therefore, we can assume
that colonization occurs in units of whole individuals (discrete state space) but the
occurrence of events is a probabilistic process. The formal definition for a stochastic
process is given by Definition 3.0.1 [2].
Definition 3.0.1. A stochastic process is a collection of random variables
{Xt(s) : t ∈ T, s ∈ S}, where T is some index set and S is the common same space
of the random variables. For each fixed t, Xt(s) denotes a single random variable
defined on S. For each fixed s ∈ S,Xt(s) corresponds to a function defined on T that
is called a sample path or a stochastic realization of the process [2].
CTMC models are governed by the Markov property
Prob{X(tt+1) = in+1|X(t0) = i0, X(t1) = i1, . . . , X(tn) = in} =
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Prob{X(tn+1) = in+1|X(tn) = in}
which simply indicates a “memoryless property”, i.e., the probability of an event
occurring depends only on the previous time step.
3.1 The Stochastic Base Model
To derive the Stochastic Base Model, which can be modified to obtain the
Stochastic Random Drug Model and the Stochastic Targeted Drug Model, we
consider the state variables to be the number of patients in a given compartment as
opposed to the proportion of the total population in that compartment as consider
in the deterministic models. We denote the new state variable as
XN = (XN1 , X
N
2 , X
N
3 , X
N
4 , X
N
5 )
T ,
where N denotes the total population and the random variables i = 1, 2, . . . , 5 are
described in Table 3.1.
Table 3.1: The Modified Definitions of Model Variables
Variables Description
XN1 (t) Number of patients colonized
with bacteria sensitive to both drugs
XN2 (t) Number of patients colonized
with bacteria resistant to drug i, i = 1
XN3 (t) Number of patients colonized
with bacteria resistant to drug i, i = 2
XN4 (t) Number of patients colonized
with bacteria resistant to both drugs
XN5 (t) Number of patients uncolonized
For the stochastic model, some of the parameters need to be modified from
the deterministic models in order to represent the number of patients accurately.
For example, β is replaced with βN = β
N
. In general it is assumed that an average
patient makes β = βNN adequate contacts with an infective per unit time, that is,
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contacts sufficient to lead to colonization [23]. For example, the probability that a
random contact with an uncolonized patient leads to a new colonization in unit time
is given by the proportion of patients uncolonized. Thus the number of new
colonizations is given by
βX = βNNX = βNN
XN5
N
= βNXN5 .
Thus, the rate of new colonizations with sensitive bacteria is now given by
βNXN5 X
N
1 . See Table 3.2 for the other modified parameters; all other parameters
are left unchanged and are described in Table 2.2.
Table 3.2: The Definition of Modified Parameters
Parameters Description Units
βN Per capita primary transmission rate = 1/N times the 1
individuals·day
colonization rate
mNS Number of admitted patients Individuals
colonized with sensitive bacteria
mNi Number of admitted patients Individuals
colonized with bacteria resistant to drug i, i = 1, 2
mN12 Number of admitted patients Individuals
colonized with bacteria resistant to both drugs
For small time intervals of length ∆t, we assume {XN(t), t ≥ 0} jumps from
the state xN to xN + vj with probability λj(x
N)∆t + o(∆t), i.e.,
Prob{XN(t+ ∆t) = xN + vj|XN(t) = xN} = λj(xN)∆t+ o(∆t), j = 1, 2, . . . , l,
xN = (xN1 , x
N
2 , x
N
3 , x
N
4 , x
N
5 )
T ∈ Z5 and λj is the transition rate for reaction j, where l
denotes the number of transitions [5]. The probability of transitioning from one
state to another state during a small time interval ∆t = dt is described by the
equations (3.1) to (3.20) where the variables SN , RN1 , R
N
2 , R
N
12, and X
N are given by
SN = xN1 = N · S,
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RN1 = x
N
2 = N ·R1,
RN2 = x
N
3 = N ·R2,
RN12 = x
N
4 = N ·R12,
XN = xN5 = N ·X
where S, R1, R2, R12, and X are the variables from the deterministic model. For
example, (3.1) describes the probability that in time dt, one individual will enter the
sensitive compartment while one individual leaves the “resistant to drug 1”
compartment. Recall that we assume a constant population, thus if an individual is
added to one compartment, an individual must also be subtracted from a different
compartment. In Figure 2.1, we notice it is not possible to have a direct transition
from R1 compartment to the S compartment. Thus, the only way for one individual
to enter S while an individual leaves R1 is if one is discharged from the hospital
from the R1 compartment, and at the same time one is admitted to the hospital.
We further note that to simplify the stochastic models, we do not consider the effect
of secondary colonization in these models. Hence, transitions involving σ in Figure
2.1 are neglected.
P{SN(t+ dt) = i+ 1, RN1 (t+ dt) = j − 1, RN2 (t+ dt) = k,RN12(t+ dt) = l,
XN(t+ dt) = m|SN(t) = i, RN1 (t) = j, RN2 (t) = k,RN12(t) = l, XN(t) = m}
= µRN1 m
N
S dt+ o(dt),
(3.1)
P{SN(t+ dt) = i+ 1, RN1 (t+ dt) = j, RN2 (t+ dt) = k − 1, RN12(t+ dt) = l,
XN(t+ dt) = m|SN(t) = i, RN1 (t) = j, RN2 (t) = k,RN12(t) = l, XN(t) = m}
= µRN2 m
N
S dt+ o(dt),
(3.2)
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P{SN(t+ dt) = i+ 1, RN1 (t+ dt) = j, RN2 (t+ dt) = k,RN12(t+ dt) = l − 1,
XN(t+ dt) = m|SN(t) = i, RN1 (t) = j, RN2 (t) = k,RN12(t) = l, XN(t) = m}
= µRN12m
N
S dt+ o(dt),
(3.3)
P{SN(t+ dt) = i+ 1, RN1 (t+ dt) = j, RN2 (t+ dt) = k,RN12(t+ dt) = l,
XN(t+ dt) = m− 1|SN(t) = i, RN1 (t) = j, RN2 (t) = k,RN12(t) = l, XN(t) = m}
= µXNmNS dt+ β
NSNXNdt+ o(dt),
(3.4)
P{SN(t+ dt) = i− 1, RN1 (t+ dt) = j + 1, RN2 (t+ dt) = k,RN12(t+ dt) = l,
XN(t+ dt) = m|SN(t) = i, RN1 (t) = j, RN2 (t) = k,RN12(t) = l, XN(t) = m}
= µSNmN1 dt+ o(dt),
(3.5)
P{SN(t+ dt) = i, RN1 (t+ dt) = j + 1, RN2 (t+ dt) = k − 1, RN12(t+ dt) = l,
XN(t+ dt) = m|SN(t) = i, RN1 (t) = j, RN2 (t) = k,RN12(t) = l, XN(t) = m}
= µRN2 m
N
1 dt+ o(dt),
(3.6)
P{SN(t+ dt) = i, RN1 (t+ dt) = j + 1, RN2 (t+ dt) = k,RN12(t+ dt) = l − 1,
XN(t+ dt) = m|SN(t) = i, RN1 (t) = j, RN2 (t) = k,RN12(t) = l, XN(t) = m}
= µRN12m
N
1 dt+ o(dt),
(3.7)
P{SN(t+ dt) = i, RN1 (t+ dt) = j + 1, RN2 (t+ dt) = k,RN12(t+ dt) = l,
XN(t+ dt) = m− 1|SN(t) = i, RN1 (t) = j, RN2 (t) = k,RN12(t) = l, XN(t) = m}
= µXNmN1 dt+ β
N(1− c1)RN1 XNdt+ o(dt),
(3.8)
P{SN(t+ dt) = i− 1, RN1 (t+ dt) = j, RN2 (t+ dt) = k + 1, RN12(t+ dt) = l,
XN(t+ dt) = m|SN(t) = i, RN1 (t) = j, RN2 (t) = k,RN12(t) = l, XN(t) = m}
= µSNmN2 dt+ o(dt),
(3.9)
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P{SN(t+ dt) = i, RN1 (t+ dt) = j − 1, RN2 (t+ dt) = k + 1, RN12(t+ dt) = l,
XN(t+ dt) = m|SN(t) = i, RN1 (t) = j, RN2 (t) = k,RN12(t) = l, XN(t) = m}
= µRN1 m
N
2 dt+ o(dt),
(3.10)
P{SN(t+ dt) = i, RN1 (t+ dt) = j, RN2 (t+ dt) = k + 1, RN12(t+ dt) = l − 1,
XN(t+ dt) = m|SN(t) = i, RN1 (t) = j, RN2 (t) = k,RN12(t) = l, XN(t) = m}
= µRN12m
N
2 dt+ o(dt),
(3.11)
P{SN(t+ dt) = i, RN1 (t+ dt) = j, RN2 (t+ dt) = k + 1, RN12(t+ dt) = l,
XN(t+ dt) = m− 1|SN(t) = i, RN1 (t) = j, RN2 (t) = k,RN12(t) = l, XN(t) = m}
= µXNmN2 dt+ β
N(1− c2)RN2 XNdt+ o(dt),
(3.12)
P{SN(t+ dt) = i− 1, RN1 (t+ dt) = j, RN2 (t+ dt) = k,RN12(t+ dt) = l + 1,
XN(t+ dt) = m|SN(t) = i, RN1 (t) = j, RN2 (t) = k,RN12(t) = l, XN(t) = m}
= µSNmN12dt+ o(dt),
(3.13)
P{SN(t+ dt) = i, RN1 (t+ dt) = j − 1, RN2 (t+ dt) = k,RN12(t+ dt) = l + 1,
XN(t+ dt) = m|SN(t) = i, RN1 (t) = j, RN2 (t) = k,RN12(t) = l, XN(t) = m}
= µRN1 m
N
12dt+ o(dt),
(3.14)
P{SN(t+ dt) = i, RN1 (t+ dt) = j, RN2 (t+ dt) = k − 1, RN12(t+ dt) = l + 1,
XN(t+ dt) = m|SN(t) = i, RN1 (t) = j, RN2 (t) = k,RN12(t) = l, XN(t) = m}
= µRN2 m
N
12dt+ o(dt),
(3.15)
P{SN(t+ dt) = i, RN1 (t+ dt) = j, RN2 (t+ dt) = k,RN12(t+ dt) = l + 1,
XN(t+ dt) = m− 1|SN(t) = i, RN1 (t) = j, RN2 (t) = k,RN12(t) = l, XN(t) = m}
= µXNmN12dt+ β
N(1− c12)RN12XNdt+ o(dt),
(3.16)
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P{SN(t+ dt) = i− 1, RN1 (t+ dt) = j, RN2 (t+ dt) = k,RN12(t+ dt) = l,
XN(t+ dt) = m+ 1|SN(t) = i, RN1 (t) = j, RN2 (t) = k,RN12(t) = l, XN(t) = m}
= µSNmNXdt+ (τ1 + τ2 + γ)S
Ndt+ o(dt),
(3.17)
P{SN(t+ dt) = i, RN1 (t+ dt) = j − 1, RN2 (t+ dt) = k,RN12(t+ dt) = l,
XN(t+ dt) = m+ 1|SN(t) = i, RN1 (t) = j, RN2 (t) = k,RN12(t) = l, XN(t) = m}
= µRN1 m
N
Xdt+ (τ2 + γ)R
N
1 dt+ o(dt),
(3.18)
P{SN(t+ dt) = i, RN1 (t+ dt) = j, RN2 (t+ dt) = k − 1, RN12(t+ dt) = l,
XN(t+ dt) = m+ 1|SN(t) = i, RN1 (t) = j, RN2 (t) = k,RN12(t) = l, XN(t) = m}
= µRN2 m
N
Xdt+ (τ1 + γ)R
N
2 dt+ o(dt),
(3.19)
P{SN(t+ dt) = i, RN1 (t+ dt) = j, RN2 (t+ dt) = k,RN12(t+ dt) = l − 1,
XN(t+ dt) = m+ 1|SN(t) = i, RN1 (t) = j, RN2 (t) = k,RN12(t) = l, XN(t) = m}
= µRN12m
N
Xdt+ γR
N
12dt+ o(dt).
(3.20)
The transition rates and reactions are summarized in Table 3.3 where
ei(j) =
 1 j = i0 j 6= i,
and where ↓ is the decrease of an individual out of a given compartment and ↑
means an increase of an individual to a given compartment. The increase ↑ and
decrease ↓ may be by direct transfer from one compartment to another (such as
colonization of an individual previously uncolonized, i.e., from X → S) or by a
discharge and corresponding admittance of a patient to two separate compartments.
In order to simulate a single realization of the stochastic model, the standard
Gillespie algorithm [5] (referred to the Stochastic Simulation Algorithm (SSA)) was
used; however, we wanted to determine the effect of the population size, N , on the
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Table 3.3: Transition rates λj(x
N) as well as the corresponding state changes vj for
the Stochastic Base Model, j = 1, 2, . . . , 5.
Event Transition Rate vj
↓ XN2 ↑ XN1 λ1 = µxN2 mNS e1 − e2
↓ XN3 ↑ XN1 λ2 = µxN3 mNS e1 − e3
↓ XN4 ↑ XN1 λ3 = µxN4 mNS e1 − e4
↓ XN5 ↑ XN1 λ4 = µxN5 mNS + βNxN1 xN5 e1 − e5
↓ XN1 ↑ XN2 λ5 = µxN1 mN1 −e1 + e2
↓ XN3 ↑ XN2 λ6 = µxN3 mN1 e2 − e3
↓ XN4 ↑ XN2 λ7 = µxN4 mN1 e2 − e4
↓ XN5 ↑ XN2 λ8 = µxN5 mN1 + βN(1− c1)xN2 xN5 e2 − e5
↓ XN1 ↑ XN3 λ9 = µxN1 mN2 −e1 + e3
↓ XN2 ↑ XN3 λ10 = µxN2 mN2 −e2 + e3
↓ XN4 ↑ XN3 λ11 = µxN4 mN2 e3 − e4
↓ XN5 ↑ XN3 λ12 = µxN5 mN2 + βN(1− c2)xN3 xN5 e3 − e5
↓ XN1 ↑ XN4 λ13 = µxN1 mN12 −e1 + e4
↓ XN2 ↑ XN4 λ14 = µxN2 mN12 −e1 + e4
↓ XN3 ↑ XN4 λ15 = µxN3 mN12 −e3 + e4
↓ XN5 ↑ XN4 λ16 = µxN5 mN12 + βN(1− c12)xN4 xN5 e4 − e5
↓ XN1 ↑ XN5 λ17 = µxN1 mNX + (τ1 + τ2 + γ)xN1 −e1 + e5
↓ XN2 ↑ XN5 λ18 = µxN2 mNX + (τ2 + γ)xN2 −e2 + e5
↓ XN3 ↑ XN5 λ19 = µxN3 mNX + (τ1 + γ)xN3 −e3 + e5
↓ XN4 ↑ XN5 λ20 = µxN4 mNX + γxN4 −e4 + e5
total resistance across several realizations to obtain an average of the expected
outcome. The value of N effects the computational time required [5]; therefore, as
done in [5], we implemented the modified explicit tau-leaping method summarized
next (full details on implementation of this method can be found in [5] and the
references therein). The main difference between the standard Gillespie Algorithm
(SSA) and the explicit tau-leaping method is in the time step taken. In the SSA
Algorithm, incremental steps are taken in time, keeping track of X(t) at each step;
whereas the explicit tau-leaping method leaps from one interval to the next by a
value of τ . Thus it is necessary to approximate the number of times a transition λj
occurs within the time interval [t, t+ τ ]. The choice of the leap value τ is
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determined by requiring relative changes in Xi to be bounded. As explained by the
author in a previous paper [5],
Let ∆Xi = Xi(t+ τ)− xi with xi being the ith component of x,
i = 1, 2, . . . , n and  be an error control parameter with 0 <  1.
In the given τ -selection procedure, τ is chosen such that
∆Xi ≤ min
{

gi
xi, 1
}
, i = 1, . . . , n,
which evidently requires the relative change in Xi to be bounded by

gi
except that Xi will never be required to change by an amount
less than 1. The value of gi is chosen such that the relative changes
in all the transitions rates will be bounded by . For example, if the
transitions rate λj has the form λj(x) = cjxi with cj being a
constant, then the reaction j is said to be first order and the
absolute change in λj(x) is given by
∆λj(x) = λj(x + ∆x)− λj(x) = cj(xi + ∆xi)− cjxi = cj∆xi.
Hence, the relative change in λi(x) is related to the relative change
in Xi by
∆λj(x)
λj(x)
= ∆xi
xi
, which implies that if we set the relative
change in Xi by  (i.e., gi = 1), then the relative change in λj is
bounded by . If the transition rate λj has the form λj(x) = cjxixr
with cj bein a constant, then the reaction j is said to be second
order and the absolution change in λj(x) is given by
∆λj(x) = cj(xi+∆xi)(xr+∆xr)−cjxixr = cjxr∆xi+cjxi∆xr+cj∆xi∆xr.
Hence, the relative change in λj(x) is related to the relative change
in Xi by
∆λj(x)
λj(x)
=
∆xi
xi
+
∆xr
xr
+
∆xi
xi
∆xr
xr
which implies that if we set the relative change in Xi by

2
and the
relative change in Xr by

2
(i.e., gi = 2, gr = 2), then the relative
change in λj is bounded by  to the first order approximation [5].
For our model, it is necessary to determine gi for each state variable
Xi, i = 1, . . . , 5. Let ∆λi(x) = λi(x + ∆x)− λi(x) with ∆x being the absolute
changes in the state variables, i = 1, 2, . . . , 20. We can see that several transitions
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are first order, because the transition only takes into account one of the state
variables. However, we must examine transitions λ4, λ8, λ12, λ16, λ17, λ18, λ19, and
λ20 because they depend on more than one state variable. Recall from Table 3.3
that transition λ4 is given by
λ4 = µx5mS + βx1x5.
Therefore,
∆λ4 = µ(x5 + ∆x5)mS + β(x1 + ∆x1)(x5 + ∆x5)− µx5mS − βx1x5
= µ∆x5mS + βx1∆x5 + β∆x1x5 + β∆x1∆x5
which implies that
∆λ4
λ4
=
µ∆x5mS + βx1∆x5 + β∆x1x5 + β∆x1∆x5
µx5mS + βx1x5
.
Using the triangle inequality and the positiveness of the state variables, we have the
following inequality
|∆λ4|
λ4
≤ |∆x5|
x5
+
|∆x5|
x5
+
|∆x1|
x1
+
|∆x1∆x5|
x1x5
≤ |∆λ4|
λ4
≤ 2|∆x5|
x5
+
|∆x1|
x1
.
If we choose
|∆x1| < 
2
x1 and |∆x4| < 
4
x5,
then the absolute relative change in λ4 is given by
|∆λ4|
λ4
< 2
( 
4
)
+

2
= .
If, in addition, we choose
|∆x2| < 
2
x2, |∆x3| < 
2
x3 and |∆x4| < 
2
x4,
we also have the following reactions will all be bounded by :
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Reaction 17:
|∆λ17|
λ17
≤ |∆x1|
x1
+
|∆x1|
x1
< 
Reaction 18:
|∆λ18|
λ18
≤ |∆x2|
x2
+
|∆x2|
x2
< 
Reaction 19:
|∆λ19|
λ19
≤ |∆x3|
x3
+
|∆x3|
x3
< 
Reaction 20:
|∆λ20|
λ20
≤ |∆x4|
x4
+
|∆x4|
x4
< .
Given these bounds on each transition, we need to set gi = 2, i = 1, . . . , 4 and
g5 = 4. Using these values of gi and the parameter values in Table 3.4, we have
plotted one realization for six different population sizes (N = 10, 25, 50, 100, 200,
and 300 patients) in Figure 3.1 using the Explicit Tau-Leaping algorithm for the
Stochastic Base Model. On each graph we have also plotted the corresponding
solution for the deterministic model. For each population size, we notice that the
majority of patients are colonized with the dual resistance (in red) similar to the
results for the deterministic model.
Table 3.4: The Values of Model Parameters for the Stochastic Base Model
Parameters Values for SSA & Explicit Tau-Leaping
βN 1
N
σ 0
γ 0.03
µ 0.10
mNS 0.70*N
mN1 0.05*N
mN2 0.05*N
mN12 0.04*N
mNX 0.16*N
c1 0.05
c2 0.05
c12 0.15
τ1 0.39
τ2 0.39
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Figure 3.1: Results for the Stochastic Base Model where N = 10, 25, 50, 100, 200,
300 compared to the corresponding deterministic results (the straight lines)
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To obtain an average result across numerous realizations (as each realization is
different), we ran 500 realizations for each of the following populations: 10, 25, 50,
100, 200, and 300 patients and compared these averages to the deterministic model.
Table 3.5 gives the average proportion of the population colonized with resistant
bacteria over one year, tf = 365 days, across the m=500 realizations, calculated
using Equations (3.21) and (3.22).
1
m
 m∑
i=1
 1
tfN
tf∫
0
[
XN4 (t)i
]
dt
 (3.21)
1
m
 m∑
i=1
 1
tfN
tf∫
0
[
XN2 (t)i +X
N
3 (t)i +X
N
4 (t)i
]
dt
 (3.22)
Table 3.5: Average Proportion of Population Colonized with Resistant Bacteria over
1 Year with varying Population sizes for the Stochastic Base Model vs. Deterministic
Base Model
Base Model Population 10 25 50 100 200 300 Deterministic
Proportion - Dual Resistance .89 .78 .74 .72 .72 .72 .72
Proportion - Total Resistance .93 .82 .77 .75 .75 .75 .75
Table 3.5 shows that the proportion of patients colonized with the dual
resistant strain is .89 when N = 10 compared to .72 for the deterministic model.
(Note that when we increase a resistant group by one patient when N = 10, we
increase the proportion by 10% whereas when we increase the resistant group by
one patient when the population size is 100, we only increase the proportion by 1%.)
Hence, for the deterministic model, it is estimated that on average across one year,
approximately 75% of the hospital population will be colonized with bacteria
resistant to both drugs. We note that the results of the deterministic model is not
dependent on the total population size, as we only consider proportions in the
deterministic model. This is an under approximation of what is simulated to occur
in a unit of a hospital where N = 10. In this case it is estimated that 89% of the
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population will be colonized with resistant bacteria. This can be seen in Figure 3.1.
When N = 10 the deterministic solution for R12 is consistently below the stochastic
model realization for R12. This results in a change in the total resistance as well.
The stochastic model indicates that on average the total proportion of patients
colonized with some type of resistant bacteria when N = 10 is approximately .93;
however, the deterministic model significantly underestimates this proportion at .75.
Once the value for N reaches approximately 100 patients or more, the two models
being to look similar. This is further evidenced in Figure 3.1 where the results of
the deterministic model are close to the realization for the stochastic model; it
appears neither below or above the stochastic model for the given realization.
3.2 Stochastic Random Drug Model
Most of the terminology used in deriving the Stochastic Base Model is the
same for the Stochastic Random Drug Model with the exception of the addition of
the third drug to this model. The term representing the addition of the new
antibiotic is found in transitions λ17, λ18, λ19, and λ20, where τ3 is the per capita
treatment rate of drug 3. Using similar probabilities of transitioning from one state
to another state as in (3.1) - (3.20), we obtain the corresponding transitions in
Table 3.6.
As done in the Stochastic Base Model, we need to calculate appropriate values
of gi for this system. All of the transitions are the same as the Stochastic Base
Model except λ17, λ18, λ19, and λ20. However, calculations (not shown here) show
values of gi can be chosen the same.
The parameter values for the Stochastic Random Drug Model are the same as
in Table 3.4 with the exception of τ1, τ2, and τ3 which are all set to 0.26. One
realization for the Stochastic Random Drug Model with population sizes of N = 10,
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Table 3.6: Transition rates λj(x
N) as well as the corresponding state changes vj for
the Stochastic Random Drug Model, j = 1, 2, . . . , 5.
Event Transition Rate vj
↓ XN2 ↑ XN1 λ1 = µxN2 mNS e1 − e2
↓ XN3 ↑ XN1 λ2 = µxN3 mNS e1 − e3
↓ XN4 ↑ XN1 λ3 = µxN4 mNS e1 − e4
↓ XN5 ↑ XN1 λ4 = µxN5 mNS + βNxN1 xN5 e1 − e5
↓ XN1 ↑ XN2 λ5 = µxN1 mN1 −e1 + e2
↓ XN3 ↑ XN2 λ6 = µxN3 mN1 e2 − e3
↓ XN4 ↑ XN2 λ7 = µxN4 mN1 e2 − e4
↓ XN5 ↑ XN2 λ8 = µxN5 mN1 + βN(1− c1)xN2 xN5 e2 − e5
↓ XN1 ↑ XN3 λ9 = µxN1 mN2 −e1 + e3
↓ XN2 ↑ XN3 λ10 = µxN2 mN2 −e2 + e3
↓ XN4 ↑ XN3 λ11 = µxN4 mN2 e3 − e4
↓ XN5 ↑ XN3 λ12 = µxN5 mN2 + βN(1− c2)xN3 xN5 e3 − e5
↓ XN1 ↑ XN4 λ13 = µxN1 mN12 −e1 + e4
↓ XN2 ↑ XN4 λ14 = µxN2 mN12 −e1 + e4
↓ XN3 ↑ XN4 λ15 = µxN3 mN12 −e3 + e4
↓ XN5 ↑ XN4 λ16 = µxN5 mN12 + βN(1− c12)xN4 xN5 e4 − e5
↓ XN1 ↑ XN5 λ17 = µxN1 mNX + (τ1 + τ2 + τ3 + γ)xN1 −e1 + e5
↓ XN2 ↑ XN5 λ18 = µxN2 mNX + (τ2 + τ3 + γ)xN2 −e2 + e5
↓ XN3 ↑ XN5 λ19 = µxN3 mNX + (τ1 + τ3 + γ)xN3 −e3 + e5
↓ XN4 ↑ XN5 λ20 = µxN4 mNX + (τ3 + γ)xN4 −e4 + e5
25, 50, 100, 200, and 300 patients is given in Figure 3.2.
As with the Stochastic Base Model, 500 realizations for each of the following
populations: 10, 25, 50, 100, 200, and 300 patients were averaged and compared to
the deterministic model. The results are given in Table 3.7.
Table 3.7: Average Proportion of Population Colonized with Resistant Bacteria over
1 Year with varying Population sizes for the Stochastic Random Drug Model vs.
Deterministic Random Drug Model
Random Drug Model Population 10 25 50 100 200 300 Deterministic
Proportion - Dual Resistance .21 .28 .31 .33 .34 .34 .35
Proportion - Total Resistance .30 .35 .37 .38 .39 .39 .39
Table 3.7 shows that the average proportion of patients colonized with the
dual resistant strain will be approximately .21 when N = 10 compared to the
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Figure 3.2: Results for Stochastic Random Drug Model where N = 10, 25, 50, 100,
200, 300 compared to the corresponding deterministic results (the straight lines)
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estimated value of .35 given by the deterministic model. Hence, the deterministic
model estimates that on average across one year approximately 35% of the hospital
population will be colonized with bacteria resistant to both drugs. Therefore, the
Deterministic Random Drug Model underestimates the impact of the new drug on
the reduction of the overall resistant population for smaller populations.
Introduction of the new drug appears to be quite effective for reducing the average
proportion of the hospital who will be colonized with dual resistant bacteria across
one year. Furthermore, in comparing Tables 3.5 and 3.7, on average the
introduction of a new drug may reduce the total level of resistance by approximately
40-63% for small hospital units of less than 50.
3.3 Stochastic Targeted Drug Model
As with the Stochastic Random Drug Model, the transitions modified by the
addition of the new antibiotic are λ17, λ18, λ19, and λ20, where τ3. Table 3.9 shows
the transitions for the Stochastic Targeted Drug Model.
As previously done in the Stochastic Base Model and the Random Drug
Model, we calculate the appropriate values of gi for the use in the explicit
tau-leaping method. Focusing on transitions λ17, λ18, λ19, and λ20, if we choose
|∆x1| < 
5
x1, |∆x2| < 
5
x2, |∆x3| < 
5
x3, |∆x4| < 
5
x4, |∆x5| < 
3
x5,
we can bound the relative change in each transition by :
Reaction 17:
|∆λ17|
λ17
≤ |∆x1|
x1
+
|∆x1|
x1
+
|∆x1|
x1
+
|∆x4|
x4
< 
Reaction 18:
|∆λ18|
λ18
≤ |∆x2|
x2
+
|∆x2|
x2
+
|∆x2|
x2
+
|∆x2|
x2
+
|∆x4|
x4
< 
Reaction 19:
|∆λ19|
λ19
≤ |∆x3|
x3
+
|∆x3|
x3
+
|∆x3|
x3
+
|∆x3|
x3
+
|∆x4|
x4
< 
Reaction 20:
|∆λ20|
λ20
≤ |∆x4|
x4
+
|∆x4|
x4
+
|∆x4|
x4
< .
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Table 3.8: Transition rates λj(x
N) as well as the corresponding state changes vj for
the Stochastic Targeted Drug Model, j = 1, 2, . . . , 5.
Event Transition Rate vj
↓ XN2 ↑ XN1 λ1 = µxN2 mNS e1 − e2
↓ XN3 ↑ XN1 λ2 = µxN3 mNS e1 − e3
↓ XN4 ↑ XN1 λ3 = µxN4 mNS e1 − e4
↓ XN5 ↑ XN1 λ4 = µxN5 mNS + βNxN1 xN5 e1 − e5
↓ XN1 ↑ XN2 λ5 = µxN1 mN1 −e1 + e2
↓ XN3 ↑ XN2 λ6 = µxN3 mN1 e2 − e3
↓ XN4 ↑ XN2 λ7 = µxN4 mN1 e2 − e4
↓ XN5 ↑ XN2 λ8 = µxN5 mN1 + βN(1− c1)xN2 xN5 e2 − e5
↓ XN1 ↑ XN3 λ9 = µxN1 mN2 −e1 + e3
↓ XN2 ↑ XN3 λ10 = µxN2 mN2 −e2 + e3
↓ XN4 ↑ XN3 λ11 = µxN4 mN2 e3 − e4
↓ XN5 ↑ XN3 λ12 = µxN5 mN2 + βN(1− c2)xN3 xN5 e3 − e5
↓ XN1 ↑ XN4 λ13 = µxN1 mN12 −e1 + e4
↓ XN2 ↑ XN4 λ14 = µxN2 mN12 −e1 + e4
↓ XN3 ↑ XN4 λ15 = µxN3 mN12 −e3 + e4
↓ XN5 ↑ XN4 λ16 = µxN5 mN12 + βN(1− c12)xN4 xN5 e4 − e5
↓ XN1 ↑ XN5 λ17 = µxN1 mNX + (T − px
N
4
N
+ γ)xN1 −e1 + e5
↓ XN2 ↑ XN5 λ18 = µxN2 mNX + (12(T − px
N
4
N
) + γ)xN2 −e2 + e5
↓ XN3 ↑ XN5 λ19 = µxN3 mNX + (12(T − px
N
4
N
) + γ)xN3 −e3 + e5
↓ XN4 ↑ XN5 λ20 = µxN4 mNX + (p+ γ)xN4 −e4 + e5
Therefore, we set gi = 5, i = 1, . . . , 4 and g5 = 3. Figures 3.3, 3.4, and 3.5
illustrate one realization for p = .15, p = .30, and p = .45 respectively. Recall p is
the total proportion of patients which can be identified as colonized with bacteria
resistant to both drugs.
Table 3.9 summarizes the average results for p = .30. If we compare the
deterministic model to the stochastic model with different population values, we can
see that the deterministic model again under estimates the effect of the addition of
the new antibiotic within a small unit of a hospital. Furthermore, comparison of
Tables 3.5 and 3.9 indicate the new drug may effectively reduce the total proportion
of patients resistant to some antibiotic on average by 44-62% over no treatment
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Figure 3.3: Results for Stochastic Targeted Drug Model where N = 10, 25, 50,
100, 200, 300 with p = .15 compared to the corresponding deterministic results (the
straight lines)
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Figure 3.4: Results for Stochastic Targeted Drug Model where N = 10, 25, 50,
100, 200, 300 with p = .30 compared to the corresponding deterministic results (the
straight lines)
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Figure 3.5: Results for Stochastic Targeted Drug Model where N = 10, 25, 50,
100, 200, 300 with p = .45 compared to the corresponding deterministic results (the
straight lines)
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when 30% of those dual resistant patients can be identified.
Table 3.9: Average Proportion of Population Colonized with Resistant Bacteria over
1 Year with varying Population sizes for the Stochastic Targeted Drug Model vs.
Deterministic Targeted Drug Model
Targeted Drug Model Population 10 25 50 100 200 300 Deterministic
Proportion - Dual Resistance .10 .12 .12 .13 .14 .14 .14
Proportion - Total Resistance .31 .34 .33 .34 .35 .35 .34
3.4 Comparison Between Stochastic Random Drug Model and
Stochastic Targeted Drug Model
If we want to compare the Stochastic Random Drug Model (SRDM) and the
Stochastic Targeted Drug Model (STDM), we see that for a small value of N , there
is a very small difference on the effect of the resistant population under different
administration protocols. Table 3.10 summarizes the average proportion of the
population colonized with a resistant strain in small population units when varying
the prescription administration protocol. When the population size is small, for
example, in an ICU where N = 10, giving the three drugs at the same rate but
randomly to patients, might even do a slightly better job of lowering the total
resistance than when we target only the dual resistant population. This does not
hold for larger populations in our model where using a targeted approach seems to
help more in the overall reduction of resistance.
Table 3.10: Total Resistance of Stochastic Models for Small Populations
Model N = 10 N = 25
SRDM Proportion .30 .35
STDM Proportion .31 .34
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CHAPTER 4
INVERSE PROBLEM
In Chapters 2 and 3, we developed both deterministic and stochastic models
to describe the spread of bacteria within a hospital. Given specified parameter
values for the deterministic and stochastic models, we illustrated the potential
trajectory for the state variables across time. The process of solving for state
variables given parameter values is known as the “forward problem”. However,
these parameter values were estimates based on literature or a “rule-of-thumb”
approach. In order to more accurately describe the spread of bacteria within a given
hospital and to assure accuracy of the model, it is necessary to assign parameter
values dependent on data measured within a hospital. Determining the parameter
values given data for the state variables is know as the “inverse problem”. Banks,
et. al. [4] say “[that] [f]inding the solutions to an inverse problem is, in general,
nontrivial because of non-uniqueness difficulties that arise. This undesirable feature
is often due to noisy data and insufficient number of observations.”
In this section, we only set up the inverse problem for solving for a select
number of parameters, which we call ~q, for the Base Model. The inverse problem
can be described by the following.
Given data, yi
d, we seek to estimate
~q = [q1, q2, . . . , qn]
such that
J(~q) =
Nt∑
i=1
|ym(ti; ~q)− yid|2
is minimized where ym(ti; ~q) is the solution to the Base Model at time ti for i = 1, 2,
. . . , Nt, given the parameter ~q and yi
d is data collected at time ti. Actual data is
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not readily available; therefore, we determine the likelihood of obtaining accurate
parameter estimates by using simulated data. We simulate data by first running
simulations to the Base Model discussed in Section 2.1 using a given set of
parameters. We then add noise to the solution using the equation:
yˆdi = ym(ti, ~q) + nl · randi
where nl represents a given noise level and randi is normally distributed random
numbers with zero mean and variance 1.0 [4]. Figure 4.1 shows the simulated noisy
data at a noise level of 1%.
Using the exact parameters and initial guesses given in Table 4.1, we try to
estimate only the parameters
~q = [β,mS,m1,m2]
at a 1% noise level initially to obtain a baseline for variability in the parameters
estimates given relatively “good” data. These parameters were chosen based on the
sensitivity analysis found in Joyner et. al. [13]. In an actual hospital setting, we
assume we may only have a limited amount of data on the type of bacteria present
at a given time. For example, if a hospital had collected data on the whole
population and fairly accurately knew the proportion colonized with each type of
bacteria, i.e., S, R1, R2, and R12 then we might obtain a different estimate for
parameter values that if we only had data on the proportion of the population
colonized with just dual resistance for instance. Therefore, we analyzed the possible
outcomes for ~q given only specified data and calculated the relative error for each
estimate. The results are given in Table 4.2. Notice that in many instances the
relative error is extremely large. These results indicate that it is necessary to search
for other techniques and/or algorithms to obtain better estimates for parameter
values. Further analysis is beyond the scope of this thesis.
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Table 4.1: Exact Parameter Values for the Base Model Inverse Problem
Parameters Exact Values Initial Guesses
β 1 1.05
mS 0.7 0.735
m1 0.06 0.063
m2 0.05 0.0525
Table 4.2: Inverse Problem - Approximate q-values & Percent Relative Error
Type ~q = [β,mS,m1,m2] % Relative Error
S, R1, R2, R12 q=[1.0006, 0.7004, 0.0603, 0.0492] r=[0.06, 0.06, 0.47, 1.69]
R1, R2, R12 q=[0.9583, 0.6510, 0.0602, 0.0491] r=[4.17, 6.10, 0.27, 1.83]
R1, R2 q=[1.8151, 1.5172, 0.0621, 0.0506] r=[81.51, 116.74, 3.46, 1.28]
R12 q=[0.8005, 0.4805, -.1380, 0.2172] r=[19.95, 31.35, 330.08, 334.48]
R1 q=[2.4463, 1.4980, 0.0618, 0.1110] r=[144.63, 114.00, 3.02, 121.96]
R2 q=[3.8465, 1.2619, 0.3355, 0.0512] r=[284.65, 80.27, 459.17, 2.41]
R1 +R2 q=[1.7711, 1.5040, 0.1372, -0.0244] r=[77.11, 114.86, 128.61, 148.76]
R1 +R2 +R12 q=[0.8315, 0.4627, 0.0628, 0.0229] r=[16.85, 33.90, 4.70, 54.27]
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Figure 4.1: Simulated Data for Each State Variable for the Base Model at a 1% Noise
Level
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CHAPTER 5
CONCLUSION
In this thesis we sought to understand how adding a new antibiotic to the
regimen affected antibiotic resistance. We began by adapting a deterministic model
from Chow, [9], to create a model of a hospital containing two groups of patients
colonized with bacteria resistant to a single antibiotic and one group colonized with
bacteria resistant to both antibiotics. This model, the Base Model, was used for
comparison purposes. With no treatment protocols, approximately 70% of the
patients within the hospital were colonized with bacteria resistant to some drug.
To incorporate the third drug, we constructed the Random Drug and Targeted
Drug Models. In the Random Drug Model, the probability of using any of the three
drugs was equal. Using this treatment protocol, the total resistance in the hospital
was reduced to 35% of the patients within the hospital colonized with some type of
resistance. The last deterministic model, the Targeted Drug Model, only allowed
treatment with the new drug on a proportion of the dual resistant patients. We ran
the model with three different proportions and results indicated that if one could
accurately identify and treat 30% of the dual resistant patients, the total resistance
drops to 32% of the patients within the hospital having some type of resistance.
Next, we developed corresponding stochastic models to more accurately model
the effects of treatment on small population sizes, such as units within a hospital.
We used continuous-time Markov Chains and the explicit tau-leaping method to
determine the average effect of the new drug for 500 realizations across one year.
We concluded that the deterministic models greatly underestimated the positive
effects of the new drug in reducing the overall proportion of patients colonized with
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resistant bacteria in small units. Furthermore, for small units there does not appear
to be a significant benefit of using one administration protocol over another.
Lastly, we gave some background and set up the inverse problem for the Base
Model. The results indicated additional techniques were needed to accurately
determine the parameters given a data set. This is considered future work.
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